{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T09:09:47Z","timestamp":1744794587943},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,25]]},"DOI":"10.7759\/cureus.30651","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T07:45:38Z","timestamp":1666683938000},"source":"Crossref","is-referenced-by-count":1,"title":["An Unusual Progression of Membranous Nephropathy"],"prefix":"10.7759","author":[{"given":"Arundhati","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anubhuti","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kartik","family":"Upreti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swetha","family":"Movva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D Ragasri","family":"Meghana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chinmay","family":"Khotele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sangamesh N","family":"Malipatil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devarsh N","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishal","family":"Venugopal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2018-135729","article-title":"Primary membranous nephropathy: comprehensive review and historical perspective","volume":"95","author":"Keri KC","year":"2019","unstructured":"Keri KC, Blumenthal S, Kulkarni V, Beck L, Chongkrairatanakul T. Primary membranous nephropathy: comprehensive review and historical perspective. Postgrad Med J. 2019, 95:23-31. 10.1136\/postgradmedj-2018-135729","journal-title":"Postgrad Med J"},{"key":"ref2","article-title":"Membranous Nephropathy","author":"Alok A","year":"2022","unstructured":"Alok A, Yadav A. Membranous Nephropathy. StatPearls, Treasure Island (FL); 2022."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck LH Jr","year":"2009","unstructured":"Beck LH Jr, Bonegio RG, Lambeau G, et al.. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009, 361:11-21. 10.1056\/NEJMoa0810457","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4103\/2231-0770.102278","article-title":"Membranous nephropathy: Treatment outline and risk stratification","volume":"2","author":"Arabi Z","year":"2012","unstructured":"Arabi Z. Membranous nephropathy: Treatment outline and risk stratification. Avicenna J Med. 2012, 2:60-4. 10.4103\/2231-0770.102278","journal-title":"Avicenna J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2217\/bmm-2018-0152","article-title":"Urine markers of podocyte dysfunction: a review of podocalyxin and nephrin in selected glomerular diseases","volume":"12","author":"Akankwasa G","year":"2018","unstructured":"Akankwasa G, Jianhua L, Guixue C, Changjuan A, Xiaosong Q. Urine markers of podocyte dysfunction: a review of podocalyxin and nephrin in selected glomerular diseases. Biomark Med. 2018, 12:927-35. 10.2217\/bmm-2018-0152","journal-title":"Biomark Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.10471013","article-title":"Association of anti-PLA\u2082R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy","volume":"9","author":"Bech AP","year":"2014","unstructured":"Bech AP, Hofstra JM, Brenchley PE, Wetzels JF. Association of anti-PLA\u2082R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2014, 9:1386-92. 10.2215\/CJN.10471013","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00873.x","article-title":"Idiopathic membranous nephropathy: definition and relevance of a partial remission","volume":"66","author":"Troyanov S","year":"2004","unstructured":"Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int. 2004, 66:1199-205. 10.1111\/j.1523-1755.2004.00873.x","journal-title":"Kidney Int"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2013.125","article-title":"Treatment of idiopathic membranous nephropathy","volume":"9","author":"Hofstra JM","year":"2013","unstructured":"Hofstra JM, Fervenza FC, Wetzels JF. Treatment of idiopathic membranous nephropathy. Nat Rev Nephrol. 2013, 9:443-58. 10.1038\/nrneph.2013.125","journal-title":"Nat Rev Nephrol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007020166","article-title":"A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy","volume":"18","author":"Jha V","year":"2007","unstructured":"Jha V, Ganguli A, Saha TK, et al.. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol. 2007, 18:1899-904. 10.1681\/ASN.2007020166","journal-title":"J Am Soc Nephrol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.12.035","article-title":"Rituximab in membranous nephropathy","volume":"6","author":"Gauckler P","year":"2021","unstructured":"Gauckler P, Shin JI, Alberici F, et al.. Rituximab in membranous nephropathy. Kidney Int Rep. 2021, 6:881-93. 10.1016\/j.ekir.2020.12.035","journal-title":"Kidney Int Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza FC","year":"2019","unstructured":"Fervenza FC, Appel GB, Barbour SJ, et al.. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med. 2019, 381:36-46. 10.1056\/NEJMoa1814427","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/121999-an-unusual-progression-of-membranous-nephropathy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:41:41Z","timestamp":1707507701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/121999-an-unusual-progression-of-membranous-nephropathy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,25]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.30651","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,25]]}}}